Metabolic disorder, Pulmonary arterial hypertension
ALNYAlnylam PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Zilebesiran (ALN-AGT) in Metabolic disorder, Pulmonary arterial hypertension. The expected timing is based on the latest available company guidance and may change.
w/ Roche ZENITH Ph3 trial. 3/5/24 Reports positive KARDIA-2 topline results. 5/9/24 Initiated KARDIA-3 study in early 2024 w/ FPI in April 2024. 2/13/25- KARDIA-3 completed enrollment. 8/30/25- Presented KARDIA-3 results at ESC '25. 10/1/25- First patient dosed in Ph3 trial. 03/30/26:- Pooled Phase 2 safety data supported acceptable profile; ZENITH Phase 3 CVOT ongoing. 08/24/26:- New clinical and real-world data to be presented at ESC 2026, August 28-31, 2026.
Verification
Confirm timing and program details against the company announcement or filing.